Hiking apps prompt warnings after separate rescues from B.C. backcountryaxiebet88 xom 。

Cristiano Ronaldo To Collaborate With MrBeast on YouTube to ‘Break the Internet’This move will mark a strategic shift in the US-India defence relationship. Published: December 7, 2024 11:05 PM IST By Edited by Pakistan may acquire Chinese J-35A fifth-generation stealth fighter for its air force. It’s a move that could significantly alter the balance of power in South Asia. India currently does not have a fifth-generation aircraft. Experts assess that in the changed geopolitical situation, the US may offer F-35A to India, which will be the answer to the Chinese J-35A for regional balance. This move will mark a strategic shift in the US-India defence relationship. China’s J-35 stealth fighter J-35A is equipped with advanced avionics, which has the ability to deploy modern weapons. If Pakistan acquires this aircraft, it can significantly increase its air warfare capabilities. It has the potential to alter the regional balance of power. However, the J-35A has not yet demonstrated its potential in real combat. India will need counter measures Due to the proximity between China and Pakistan, it is believed that Islamabad can get these fighters. The inclusion of the J-35A in Pakistan’s arsenal means that India will need strong counter-measures especially when China has a fleet of fifth-generation fighter aircraft like the J-20, which is constantly growing. The evolving situation in South Asia could pose an opportunity for the Pentagon to strengthen its strategic partnership with India and contain China’s influence. The offer of the F-35A to India could provide a decisive technological advantage. The F-35A is currently considered among the most advanced fighters in the world, having proven its capabilities in combat. Obstacles in acquiring American F-35 However, there are obstacles in acquiring the American F-35A for India. India has bought the S-400 air defense system from Russia, which could complicate this deal. US rules regarding the deployment of F-35 to countries possessing Russian systems are very strict. Experts suggest that to reduce these risks, the US can impose conditions for the sale of F-35A to India. Under these conditions, F-35 operations could be kept away from S-400 batteries. Simultaneously, more surveillance and inter-operation measures should be implemented with the US forces to protect sensitive technologies. Challenge for India Before acquiring the F-35A, India will have to carefully look at its possible implications. The F-35A is known for its high acquisition and maintenance costs. Choosing the F-35 could divert resources and attention from India’s indigenous fighter jet programmes. In addition, the acceptance of the F-35A could potentially strain India’s long-standing defense relationship with Russia. For breaking news and live news updates, like us on or follow us on and . Read more on Latest on . TopicsSouthgate considering career outside of football

Michigan athletic director Warde Manuel gets 5-year contract extensionRested Rangers aim to get right vs. surging PenguinsEli Lilly is spending another $3 billion to bulk up manufacturing as the drugmaker seeks to stoke production of some blockbuster drugs and future products. Lilly said Thursday it will expand a Kenosha County, Wisconsin, factory it bought early this year, and the investment will help meet growing demand for injectable products like its diabetes and obesity drugs, Mounjaro and Zepbound. Those drugs brought in a combined $4.4 billion in sales for Lilly in this year’s third quarter. The drugmaker plans to start construction of the expansion next year. Lilly also announced other multibillion-dollar manufacturing expansion projects near its Indianapolis headquarters earlier this year. Eli Lilly and Co. said Thursday that it has slated more than $23 billion to construct, expand or acquire manufacturing sites worldwide since 2020. The Nov. 29 print edition of The Business Journal included The huge rally for U.S. stocks lost momentum on Thursday Eli Lilly is spending another $3 billion to bulk up Known across the globe as the stuck astronauts, Butch Wilmore

LA JOLLA, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announces the study update and interim analysis results from the Company’s COMBAT-ALS Phase 2b/3 clinical trial of MN-166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS) will be presented at the 35th International Symposium on ALS/MND held December 6-8, 2024 in Montreal, Canada. The highlights of the presentation, titled, “ COMBAT-ALS Phase 2b/3 Trial of MN-166 (Ibudilast) in ALS: Trial Update and Interim Analysis Results” ( Abstract # 302), include: Study Update: As of November 15, 2024, a total of 217 participants have been enrolled and 183 participants were assigned to either MN-166 or placebo group. Pre-defined interim analysis was conducted to evaluate the correlation between the 6-month and 12-month data and assess the 12-month double-blind phase trial design. A subset of patients from the full analysis set who had ALSFRS-R data at 6 months and at least one post-6-month data point. Correlation analysis of the Combined Assessment of Function and Survival (CAFS) scores at 6 and 12 months as well as modified CAFS scores and ALSFRS-R scores were evaluated. Positive correlations were observed between the 6-month and 12-month data for CAFS score (0.71), modified CAFS score (0.70), and ALSFRS-R (0.69). [Note: Values in parentheses are Spearman Rank Correlation coefficients] Positive correlations were also observed for Bulbar score (0.74), Fine motor score (0.71), and Gross motor score (0.67), but not for Respiratory score. [Note: Values in parentheses are Spearman Rank Correlation coefficients] Interim analysis results were reviewed and validated by an external independent Data Safety Monitoring Board (DSMB), which recommended that the trial continue as per the protocol. MediciNova CMO and Director Kazuko Matsuda commented, "The interim analysis showed a positive correlation between the 6-month and 12-month data. We considered a change in the treatment period, decided to continue the trial with the current treatment plan based on the DSMB's recommendation. We believe these results will be valuable in designing studies for rapidly progressing diseases like ALS. As of mid-November 2024, over 200 patients have been enrolled and more than 180 patients assigned, if we continue to actively enroll in the COMBAT-ALS study, we expect to complete patient assignments by June 2025 with trial results expected in 2026. Concurrently, we have been supporting continued treatment for those patients wishing to continue MN-166 treatment after the 6-month open-label phase via the FDA's Expanded Access Program (EAP). Next year, the NIH-funded, large-scale Expanded Access Program trial is set to begin, and we look forward to the opportunity to provide access to MN-166 to more ALS patients.” About MN-166 (ibudilast) MN-166 (ibudilast) is a small molecule compound that inhibits phosphodiesterase type-4 (PDE4) and inflammatory cytokines, including macrophage migration inhibitory factor (MIF). It is in late-stage clinical development for the treatment of neurodegenerative diseases such as ALS (amyotrophic lateral sclerosis), progressive MS (multiple sclerosis), and DCM (degenerative cervical myelopathy); and is also in development for glioblastoma, Long COVID, CIPN (chemotherapy-induced peripheral neuropathy), and substance use disorder. In addition, MN-166 (ibudilast) was evaluated in patients that are at risk for developing acute respiratory distress syndrome (ARDS). About MediciNova MediciNova, Inc. is a clinical-stage biopharmaceutical company developing a broad late-stage pipeline of novel small molecule therapies for inflammatory, fibrotic, and neurodegenerative diseases. Based on two compounds, MN-166 (ibudilast) and MN-001 (tipelukast), with multiple mechanisms of action and strong safety profiles, MediciNova has 11 programs in clinical development. MediciNova’s lead asset, MN-166 (ibudilast), is currently in Phase 3 for amyotrophic lateral sclerosis (ALS) and degenerative cervical myelopathy (DCM) and is Phase 3-ready for progressive multiple sclerosis (MS). MN-166 (ibudilast) is also being evaluated in Phase 2 trials in Long COVID and substance dependence. MN-001 (tipelukast) was evaluated in a Phase 2 trial in idiopathic pulmonary fibrosis (IPF) and a second Phase 2 trial in non-alcoholic fatty liver disease (NAFLD) is ongoing. MediciNova has a strong track record of securing investigator-sponsored clinical trials funded through government grants. Statements in this press release that are not historical in nature constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding the future development and efficacy of MN-166, MN-001, MN-221, and MN-029. These forward-looking statements may be preceded by, followed by, or otherwise include the words "believes," "expects," "anticipates," "intends," "estimates," "projects," "can," "could," "may," "will," "would," “considering,” “planning” or similar expressions. These forward-looking statements involve a number of risks and uncertainties that may cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Factors that may cause actual results or events to differ materially from those expressed or implied by these forward-looking statements include, but are not limited to, risks of obtaining future partner or grant funding for development of MN-166, MN-001, MN-221, and MN-029 and risks of raising sufficient capital when needed to fund MediciNova's operations and contribution to clinical development, risks and uncertainties inherent in clinical trials, including the potential cost, expected timing and risks associated with clinical trials designed to meet FDA guidance and the viability of further development considering these factors, product development and commercialization risks, the uncertainty of whether the results of clinical trials will be predictive of results in later stages of product development, the risk of delays or failure to obtain or maintain regulatory approval, risks associated with the reliance on third parties to sponsor and fund clinical trials, risks regarding intellectual property rights in product candidates and the ability to defend and enforce such intellectual property rights, the risk of failure of the third parties upon whom MediciNova relies to conduct its clinical trials and manufacture its product candidates to perform as expected, the risk of increased cost and delays due to delays in the commencement, enrollment, completion or analysis of clinical trials or significant issues regarding the adequacy of clinical trial designs or the execution of clinical trials, and the timing of expected filings with the regulatory authorities, MediciNova's collaborations with third parties, the availability of funds to complete product development plans and MediciNova's ability to obtain third party funding for programs and raise sufficient capital when needed, and the other risks and uncertainties described in MediciNova's filings with the Securities and Exchange Commission, including its annual report on Form 10-K for the year ended December 31, 2023 and its subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Undue reliance should not be placed on these forward-looking statements, which speak only as of the date hereof. MediciNova disclaims any intent or obligation to revise or update these forward-looking statements. INVESTOR CONTACT : David H. Crean, Ph.D. Chief Business Officer MediciNova, Inc info@medicinova.com